A daily compilation of articles, manuscripts, and news focused on the ADC market and compiled for the scientists who are making the cure everyday.
Thursday, May 16, 2019
Daiichi gets one out of two drugs approved
In case you hadn't already heard about this. Now you have:
https://endpts.com/daiichi-sankyo-disappointed-as-fda-experts-spurn-aml-drug-but-vote-in-favor-of-rare-tumor-drug/
https://www.reuters.com/article/us-daiichi-sankyo-fda/fda-advisory-panel-votes-against-daiichi-sankyos-cancer-treatment-idUSKCN1SK2JP
https://www.fiercebiotech.com/biotech/daiichi-s-leukemia-drug-falls-amid-fda-adcomm-s-trial-concerns
https://finance.yahoo.com/news/daiichi-sankyo-announces-outcome-fda-220200236.html
https://www.biospace.com/article/daiichi-sankyo-receives-a-yes-and-no-from-fda-advisory-panel/
https://www.evaluate.com/vantage/articles/news/snippets/us-backs-only-one-two-daiichi-oncology-projects-only-beginning
Wow.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment